Seeking Alpha

Venaxis, Inc. (APPY)

  • Mar. 26, 2013, 8:09 PM
    Venaxis Inc. (APPY) climbs in the post-trade session after providing an update on its clinical and commercial activities, reporting in its 10-K that it continues to enroll patients into its ongoing clinical study of APPY1, and it anticipates completing the study and potentially filing with the FDA for regulatory clearance by year end. Read more on its Business Update Conference Call Here: Business Update Transcript. Shares +5% AH.
    | Mar. 26, 2013, 8:09 PM | Comment!
Company Description
Venaxis Inc is engaged in the development and commercialization of products that address unmet diagnostic and therapeutic needs.